tiprankstipranks
Atea Pharmaceuticals files $500M mixed securities shelf
PremiumThe FlyAtea Pharmaceuticals files $500M mixed securities shelf
2M ago
Atea Pharmaceuticals Phase 3 SUNRISE-3 trial did not meet primary endpoint
Premium
The Fly
Atea Pharmaceuticals Phase 3 SUNRISE-3 trial did not meet primary endpoint
4M ago
Atea Pharma publishes data on metabolic activation pathway of bemnifosbuvir
Premium
The Fly
Atea Pharma publishes data on metabolic activation pathway of bemnifosbuvir
5M ago
Is AVIR a Buy, Before Earnings?
PremiumPre-EarningsIs AVIR a Buy, Before Earnings?
8M ago
Atea Pharmaceuticals announces presentation on safety profile of bemnifosbuvir
Premium
The Fly
Atea Pharmaceuticals announces presentation on safety profile of bemnifosbuvir
9M ago
Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
Premium
The Fly
Atea Pharmaceuticals completes patient enrollment in Phase 3 SUNRISE-3 trial
10M ago
Buy/Sell: Wall Street’s top 10 stock calls this week
PremiumThe FlyBuy/Sell: Wall Street’s top 10 stock calls this week
1y ago
Atea Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
Premium
The Fly
Atea Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
1y ago
Atea Pharmaceuticals reports Q2 EPS (34c), consensus (47c)
Premium
The Fly
Atea Pharmaceuticals reports Q2 EPS (34c), consensus (47c)
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100